| 000 | 01772 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516210931.0 | ||
| 264 | 0 | _c20160405 | |
| 008 | 201604s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.3109/10428194.2014.916805 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTabarroki, Ali | |
| 245 | 0 | 0 |
_aRuxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cFeb 2015 |
||
| 300 |
_a497-9 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aAzacitidine _xadministration & dosage |
| 650 | 0 | 4 |
_aDNA Modification Methylases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aDecitabine |
| 650 | 0 | 4 |
_aFatigue _xprevention & control |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xdrug therapy |
| 650 | 0 | 4 |
_aPyrazoles _xadministration & dosage |
| 650 | 0 | 4 | _aPyrimidines |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSaunthararajah, Yogen | |
| 700 | 1 | _aVisconte, Valeria | |
| 700 | 1 | _aCinalli, Tracy | |
| 700 | 1 | _aColaluca, Kristin | |
| 700 | 1 | _aRogers, Heesun J | |
| 700 | 1 | _aSekeres, Mikkael A | |
| 700 | 1 | _aDuong, Hien K | |
| 700 | 1 | _aStein, Brady L | |
| 700 | 1 | _aTiu, Ramon V | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 56 _gno. 2 _gp. 497-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428194.2014.916805 _zAvailable from publisher's website |
| 999 |
_c23769501 _d23769501 |
||